abstract: BACKGROUND: An optimal outcome of closed treatment of a @entity2 may depend on accurate reduction and adequate immobilization. It has been suggested that the use of finger-trap traction results in a better reduction and a lower rate of redisplacement than manual manipulation does, but to our knowledge these concepts have never been evaluated scientifically. We compared these two methods in a prospective, randomized controlled trial. METHODS: Two hundred and twenty-three @entity0 with 225 displaced @entity2 were randomized to treatment with closed reduction with either finger-trap traction (112 @entity0 ) or manual manipulation (111 @entity0 ). The @entity1 were assessed radiographically by measurement of the radial angle, dorsal tilt, and radial shortening before reduction, immediately after reduction, and at one and five weeks after reduction. RESULTS: The groups were comparable with regard to age, sex, side of injury, @entity1 grade, and amount of displacement at presentation. No significant differences were found between the alignment of the @entity1 in the two treatment groups at any time. With dorsal tilt of <10 degrees and radial shortening of <5 mm considered acceptable, the two techniques both produced an 87% rate of satisfactory reductions. However, the percentages of @entity1 in an acceptable alignment were only 57% and 50% at one week after finger-trap traction and manual manipulation, respectively, and only 27% and 32% at five weeks. The failure rates did not differ significantly between the two groups. CONCLUSIONS: The two methods of @entity1 reduction did not differ with regard to the eventual position of the @entity1 or the rate of failure. Although closed reduction was successful for the majority of @entity1 , most redisplaced substantially during the period of cast immobilization.

title: XXXX : comparison of manual manipulation and finger-trap traction: a prospective, randomized study.

answer: @entity2


abstract: BACKGROUND: The main causative agents of @entity12 are @entity10 , tiny, gram-negative bacilli. The disease usually has a benign course with the development of a papule at the inoculation site, followed by regional @entity11 . In most cases, complete resolution occurs, but in immunocompromised hosts, the course of the disease can be aggravated. CASE REPORT: A @entity0 received @entity8 and @entity3 for 3 months due to @entity4 . He developed @entity2 , @entity9 and @entity7 under @entity8 therapy. Dark red indurations with central @entity5 at his right thigh revealed a further problem apart from the @entity8 -induced @entity6 and immunosuppression. The @entity5 were the remainders of recurrent scratches from the @entity0 's cat. The patient's antibody titers against @entity10 remained low and @entity1 was only for a short time to be observed, this reaction obviously weakened as a result of the immunosuppression. However, the typical course, the exclusion of other reasons for the @entity9 and the rapid improvement of the @entity0 's condition after antibiotic treatment ascertained the diagnosis. CONCLUSIONS: In immunocompromised hosts, diseases with a typically benign course can become severe and life-threatening illnesses. Ownership of pets should be taken into consideration before onset of an immunosuppressive therapy.

title: XXXX in an immunocompromised host.

answer: @entity12


abstract: OBJECTIVE: To use the Rod-and-Frame Test (RFT) as a quantification of the perception of verticality in subjects with and without @entity1 . DESIGN: Cohort study comparing perception of verticality in symptomatic subjects with @entity1 versus a control group. SETTING: Both groups were selected from 2 urban chiropractic offices treating typical neuromusculoskeletal conditions from the general community in Canada. @entity0 : Nineteen subjects (11 @entity0 , 8 @entity0 ) with uncomplicated mechanical @entity1 and 17 (7 @entity0 , 10 @entity0 ) asymptomatic subjects. INTERVENTION: The RFT offers a noninvasive method of measuring spatial orientation or the perception of verticality. Studies of the RFT indicate that performance is reliable. The RFT requires subjects to set a luminescent rod to the true vertical in the presence and absence of a luminescent background frame. MAIN OUTCOME MEASURE: The amount of rotation was measured and recorded by a dial on the back of the device. RESULTS: Two-way analysis of variance showed statistically significant differences in judging vertical between symptomatic and asymptomatic subjects. Unpaired t tests for each test situation and the Tukey post hoc test showed statistical differences for both groups. CONCLUSION: There may be a direct connection between the structures that provide internal cues for the body's ability to sense verticality and nociceptive influences affecting the afference of these structures. The overshoot of the symptomatic group could indicate the search for additional proprioceptive information.

title: Effect of XXXX on verticality perception: a cohort study.

answer: @entity1


abstract: OBJECTIVE: To assess the efficacy of @entity3 in @entity0 presenting with troublesome reflux symptoms. DESIGN: Randomized, double-blind, parallel-group, placebo-controlled comparison. SETTING: Primary care. SUBJECTS: @entity0 were recruited using a symptom-based questionnaire for diagnosis of @entity1 . INTERVENTIONS: After endoscopy, @entity0 without endoscopic @entity1 were randomized to @entity3 20 mg (Ome20), @entity3 10 mg (Ome10) or placebo once daily for 4 weeks (n = 261) and those with @entity1 (except circumferential/ulcerative) were randomized to receive either Ome20 or Ome10 once daily for 4 weeks (n = 277). @entity0 not symptom-free at 4 weeks received open treatment with Ome20 once daily for a further 4 weeks. Those symptom-free at 4-8 weeks were followed up for 6 months off treatment, to see whether their symptoms recurred. MAIN OUTCOME MEASURE: Complete upper GI symptom relief during week 4 on Ome20 or Ome10 in @entity0 with or without endoscopic @entity1 . RESULTS: Forty one percent of all @entity0 on Ome20 and 35% on Ome10 reported complete relief from @entity2 during week 4, whilst 73% of the @entity0 on Ome20 and 62% on Ome10 obtained sufficient control. Complete relief during week 4 was reported by 19% of endoscopy-negative @entity0 on placebo, and sufficient control by 35%. Endoscopic healing at 4 weeks occurred in 76% of @entity1 @entity0 on Ome20 and in 56% on Ome10. After 6 months off treatment, 90% of @entity0 with @entity1 and 75% of endoscopy-negative @entity0 reported symptomatic relapse. CONCLUSION: Both 10 mg and 20 mg of @entity3 gave effective relief of symptoms, although 20 mg gave superior healing in @entity0 with @entity1 . After cessation of treatment, symptomatic relapse was rapid and frequent in both endoscopy-positive and endoscopy-negative @entity0 .

title: XXXX in primary care: an international study of different treatment strategies with @entity3 . International GORD Study Group.

answer: @entity1


abstract: OBJECTIVE: To assess the efficacy of @entity3 in @entity0 presenting with troublesome reflux symptoms. DESIGN: Randomized, double-blind, parallel-group, placebo-controlled comparison. SETTING: Primary care. SUBJECTS: @entity0 were recruited using a symptom-based questionnaire for diagnosis of @entity1 . INTERVENTIONS: After endoscopy, @entity0 without endoscopic @entity1 were randomized to @entity3 20 mg (Ome20), @entity3 10 mg (Ome10) or placebo once daily for 4 weeks (n = 261) and those with @entity1 (except circumferential/ulcerative) were randomized to receive either Ome20 or Ome10 once daily for 4 weeks (n = 277). @entity0 not symptom-free at 4 weeks received open treatment with Ome20 once daily for a further 4 weeks. Those symptom-free at 4-8 weeks were followed up for 6 months off treatment, to see whether their symptoms recurred. MAIN OUTCOME MEASURE: Complete upper GI symptom relief during week 4 on Ome20 or Ome10 in @entity0 with or without endoscopic @entity1 . RESULTS: Forty one percent of all @entity0 on Ome20 and 35% on Ome10 reported complete relief from @entity2 during week 4, whilst 73% of the @entity0 on Ome20 and 62% on Ome10 obtained sufficient control. Complete relief during week 4 was reported by 19% of endoscopy-negative @entity0 on placebo, and sufficient control by 35%. Endoscopic healing at 4 weeks occurred in 76% of @entity1 @entity0 on Ome20 and in 56% on Ome10. After 6 months off treatment, 90% of @entity0 with @entity1 and 75% of endoscopy-negative @entity0 reported symptomatic relapse. CONCLUSION: Both 10 mg and 20 mg of @entity3 gave effective relief of symptoms, although 20 mg gave superior healing in @entity0 with @entity1 . After cessation of treatment, symptomatic relapse was rapid and frequent in both endoscopy-positive and endoscopy-negative @entity0 .

title: @entity1 in primary care: an international study of different treatment strategies with XXXX . International GORD Study Group.

answer: @entity3


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the @entity4 -angiotensin system in @entity5 and XXXX in transgenic @entity3 @entity2 carrying both @entity0 @entity4 and @entity6 genes.

answer: @entity1


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the @entity4 -angiotensin system in @entity5 and @entity1 in transgenic @entity3 @entity2 carrying both @entity0 @entity4 and XXXX genes.

answer: @entity6


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the @entity4 -angiotensin system in XXXX and @entity1 in transgenic @entity3 @entity2 carrying both @entity0 @entity4 and @entity6 genes.

answer: @entity5


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the XXXX -angiotensin system in @entity5 and @entity1 in transgenic @entity3 @entity2 carrying both @entity0 @entity4 and @entity6 genes.

answer: @entity4


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the @entity4 -angiotensin system in @entity5 and @entity1 in transgenic @entity3 @entity2 carrying both @entity0 XXXX and @entity6 genes.

answer: @entity4


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the @entity4 -angiotensin system in @entity5 and @entity1 in transgenic @entity3 XXXX carrying both @entity0 @entity4 and @entity6 genes.

answer: @entity2


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the @entity4 -angiotensin system in @entity5 and @entity1 in transgenic XXXX @entity2 carrying both @entity0 @entity4 and @entity6 genes.

answer: @entity3


abstract: Tsukuba @entity3 @entity2 (THMs) are @entity2 carrying @entity0 @entity4 and @entity6 genes. The aim of this study was to evaluate the role of the @entity4 -angiotensin system (RAS) in @entity5 and @entity1 in THMs. After a 2-wk control period, 10-wk-old THMs were treated with @entity8 (ACEI group) or @entity7 ( @entity7 group) or left untreated (control group) for 8 wk. C57BL/6 @entity2 of similar age (wild group) were used as normal controls. Systolic blood pressure and urinary albumin excretion were measured once a week. All @entity2 were sacrificed at 20 wk of age, and heart to body weight ratio, cardiac myocyte diameter, @entity1 index, and glomerular size were measured. Fibronectin expression was also evaluated. At 20 wk of age, systolic blood pressure and urinary albumin excretion in the control group were significantly higher than those in the wild group and significantly lower than those in the ACEI and @entity7 groups. Heart to body weight ratio and cardiac myocyte diameter were significantly higher in the @entity7 and control groups than in the other groups. @entity1 index and glomerular size were also significantly higher in the control group than in the other groups, and there were significant differences between the ACEI and @entity7 groups in these variables. Fibronectin expression was marked in the control and @entity7 groups. These findings suggest that the RAS plays an important role in @entity5 in THMs, but that both the RAS and elevation of blood pressure contribute to the pathogenesis of @entity1 .

title: Role of the @entity4 -angiotensin system in @entity5 and @entity1 in transgenic @entity3 @entity2 carrying both XXXX @entity4 and @entity6 genes.

answer: @entity0


abstract: UNASSIGNED: OBJECT @entity4 are well suited to resection by a minimal-access endoscopic technique. Validation of this approach requires prospective outcome studies to determine the impact on quality of life (QOL). This study aims to assess the effect of endoscopic pituitary @entity3 resection on site-specific and sinonasal-related QOL before and after endoscopic surgery using validated instruments. METHODS Consecutive adult @entity0 undergoing endoscopic endonasal resection of pituitary @entity3 were prospectively enrolled from a single tertiary care center. All @entity0 completed the Anterior Skull Base Questionnaire (ASBQ) and the 22-Item Sino-Nasal Outcome Test (SNOT-22) preoperatively and then at regular intervals after surgery to assess their perceived QOL with regard to hormonal, surgical, and anatomical factors. RESULTS Eighty-one of 114 @entity0 were eligible for study; median follow-up was 16 months. This cohort included 24 (29.6%) nonsecreting macroadenomas and 57 (70.4%) hypersecreting @entity1 . There was significant improvement in the mean ASBQ score at 12 weeks, 6 months, and 1 year after surgery (p < 0.05), while postoperative SNOT-22 scores, at the same time points, showed no significant difference from preoperative scores. Both ASBQ and SNOT-22 scores showed transient worsening at 3 weeks postoperatively. Subtotal resection correlated with worse QOL, both overall and among @entity0 with hypersecreting @entity1 (p < 0.05). Extrasellar @entity1 extension, intraoperative CSF leakage, and a reconstruction technique during surgery did not impact postoperative QOL. @entity2 did not significantly alter QOL. There were no postoperative CSF leaks in this series. CONCLUSIONS Endoscopic resection of pituitary @entity3 is associated with long-term improvements in site-specific QOL and stability in sinonasal QOL when assessed pre- and postoperatively with validated instruments. Subtotal resection was the only factor that negatively impacted postoperative QOL. Therefore, gross-total resection should be attempted for all @entity0 to optimize QOL after surgery.

title: Preservation of multidimensional quality of life after endoscopic pituitary XXXX resection.

answer: @entity3


abstract: The authors report a complication of catheter ablation that, to their knowledge, has never been previously reported. A 63-year-old @entity0 had undergone successful transvenous catheter thermoablation for @entity2 . The @entity0 remained well until 3 days prior to further admission when he noticed itching in the right frontal area of his scalp. On palpating his scalp, he discovered a metallic body projecting out of it and he proceeded to extract 20 cm of wire from his head. The following day a progressive left @entity3 developed, and the @entity0 experienced a deteriorating level of consciousness. A CT scan of the brain showed a right frontotemporal intraparenchymal hemorrhage and revealed a metallic structure in the middle of the @entity4 . The @entity4 was evacuated and a decompressive craniotomy was performed. The guidewire was identified, but it was only possible to extract part of it. It was covered by fibrous tissue, secondary to inflammatory reaction. To the authors' knowledge, this is the first report of guidewire-induced @entity1 . The guidewire apparently had not been removed and had spontaneously migrated from the heart to the brain and beyond to the scalp where it then exited the @entity0 's head. The @entity0 had been well before he attempted to pull out the wire. Earlier identification of the iatrogenic complication of a retained guidewire might have prevented the fatal outcome in this case.

title: An unusual complication of XXXX ablation: case report.

answer: @entity2


abstract: @entity1 ) is able to subvert the host cell replication machinery so as to foster viral reproduction. Specifically, @entity2 is known to induce expression of proliferation antigens such as Ki67 and proliferative cell nuclear antigen ( @entity3 ) in differentiated keratinocytes which have ceased to replicate. In order to determine whether @entity5 or cyclin E deregulation is also a feature of @entity2 , an immunohistochemical investigation of @entity5 , cyclin E, Ki67, and @entity3 expression has been carried out in 38 cases of HPV 6/11-related @entity6 ( @entity6 ). Results were compared with those obtained from 15 @entity0 . Whereas 35 (92.1 per cent) @entity6 samples exhibited positive nuclear immunostaining for cyclin E, no @entity5 immunoreaction was detected in any of the @entity6 samples studied. All @entity0 showed immunostaining for both cyclins. All @entity6 cases revealed a positive immunoreaction for Ki67 and 33 for @entity3 , both in the parabasal and in the differentiated upper epithelial layers. Parabasal keratinocytes of @entity0 were always positive for both Ki67 and @entity3 . These results indicate that in the onslaught of HPV 6/11 upon the keratinocyte replication machinery, cyclin E, @entity3 , and Ki67 are amongst the targeted cell cycle modulators, whereas @entity5 is spared the main effects of virus-cell interplay. In contrast, both cyclins seem to be induced in @entity4 , @entity7 .

title: expression patterns of cyclins D1 and E in XXXX in comparison with @entity0 .

answer: @entity6


abstract: @entity1 ) is able to subvert the host cell replication machinery so as to foster viral reproduction. Specifically, @entity2 is known to induce expression of proliferation antigens such as Ki67 and proliferative cell nuclear antigen ( @entity3 ) in differentiated keratinocytes which have ceased to replicate. In order to determine whether @entity5 or cyclin E deregulation is also a feature of @entity2 , an immunohistochemical investigation of @entity5 , cyclin E, Ki67, and @entity3 expression has been carried out in 38 cases of HPV 6/11-related @entity6 ( @entity6 ). Results were compared with those obtained from 15 @entity0 . Whereas 35 (92.1 per cent) @entity6 samples exhibited positive nuclear immunostaining for cyclin E, no @entity5 immunoreaction was detected in any of the @entity6 samples studied. All @entity0 showed immunostaining for both cyclins. All @entity6 cases revealed a positive immunoreaction for Ki67 and 33 for @entity3 , both in the parabasal and in the differentiated upper epithelial layers. Parabasal keratinocytes of @entity0 were always positive for both Ki67 and @entity3 . These results indicate that in the onslaught of HPV 6/11 upon the keratinocyte replication machinery, cyclin E, @entity3 , and Ki67 are amongst the targeted cell cycle modulators, whereas @entity5 is spared the main effects of virus-cell interplay. In contrast, both cyclins seem to be induced in @entity4 , @entity7 .

title: expression patterns of cyclins D1 and E in @entity6 in comparison with XXXX .

answer: @entity0


abstract: UNASSIGNED: Chitosan oligosaccharide (COS), a biomaterial derived from chitin, is absorbed by intestinal epithelia without @entity4 and has diverse biological activities including intestinal epithelial function. However, the mode of action is still unclear. This study aimed to investigate the effect of COS on @entity7 -activated protein kinase (AMPK) in intestinal epithelial cells (IEC) and its potential applications in the @entity5 benefited from AMPK activation. COS with molecular weights (MW) from 5,000Da to 14,000Da induced AMPK activation in T84 cells. That with MW of 5,000-Da was the most potent polymer and was used in the subsequent experiments. COS also activated AMPK in other IEC including HT-29 and Caco-2 cells. Mechanism of COS-induced AMPK activation in T84 cells involves @entity3 -sensing receptor (CaSR)-phospholipase C (PLC)-IP3 receptor channel-mediated @entity3 release from endoplasmic reticulum (ER). In addition, COS promoted tight junction assembly in T84 cells in an AMPK-dependent manner. COS also inhibited NF-kB transcriptional activity and NF-kB-mediated inflammatory response and barrier disruption via AMPK-independent mechanisms. Interestingly, luminal exposure to COS suppressed cholera toxin-induced intestinal fluid secretion by    30% concurrent with AMPK activation in a @entity1 closed loop model. Importantly, oral administration of COS prevented the development of aberrant crypt foci in a @entity1 model of @entity6 -associated @entity0 ( @entity0 ) via a mechanism involving AMPK activation-induced b-catenin suppression and @entity2 activation. Collectively, this study reveals a novel action of COS in activating AMPK via CaSR-PLC-IP3 receptor channel-mediated @entity3 release from ER. COS may be beneficial in the treatment of secretory diarrheas and @entity0 chemoprevention.

title: Activation of AMPK by chitosan oligosaccharide in intestinal epithelial cells: Mechanism of action and potential applications in XXXX .

answer: @entity5


abstract: OBJECTIVE: Development of a test to screen excess salt intake (ESI) in @entity1 @entity0 . METHODS: @entity1 subjects living in Paris area have been included. A 24-hour urinary @entity3 collection has been performed the day before the visit for a day hospital. A food diary was completed on the day of the urine collection and validated after an interview with a dietetician. An ESI was defined by a urinary @entity3  >=   200mmol/d. Clinical or food characteristics associated to an ESI were retained for the ExSel Test variables. A ROC curve was performed to determine the optimal score for the ExSel Test in detection of ESI in @entity1 @entity0 . RESULTS: One hundred and forty-eight @entity1 @entity0 have been included living in the   le-de-France area. ESI was observed in 19% with a higher frequency in @entity0 . Seven major determinants of ESI have been identified and are the questions that constitute the ExSel Test. A positive response assigns points: @entity0 (1); BMI  >  30 (2); bread  4  or 5  pieces per day (1) or more than 6  pieces; cheese at least 1  time per day (2); charcuterie at least 2  times per week (2); use of processed broth or pilaf (1); food rich in hidden salt (pizza, cheeseburger, quiche, shrimp, @entity2 chips, smoked fish, olive) at least 2  times per week (1). The ROC curve analysis shows that a score of 5  or more has the best Youden index with a sensitivity of 0.63, specificity of 0.95, @entity4 of 0.75, NPV of 0.92. CONCLUSIONS: In @entity1 subjects, an excessive salt intake can be detected by the realization of the ExSel Test based only on a simple food-questionnaire and some clinical parameters. For a clinical use of the ExSel Test, an electronic version is available on http://www.comitehta.org.

title: [Development and evaluation of ExSel Test to screen for excess salt intake in XXXX subjects].

answer: @entity1


abstract: @entity4 ( @entity4 ) does not manifest clinically until 80 % of striatal @entity6 is reduced, thus most @entity5 takes place before the @entity0 presents clinical symptoms. Therefore, it is important to develop preventive strategies for this disease. In the experimental models of @entity4 , @entity9 ion (MPP+) and @entity7 induce @entity2 in dopaminergic neurons. Neuroprotectin D1 (NPD1) displays neuroprotection in cells undergoing proteotoxic and oxidative stress. In the present report, we established an in vitro model using a primary neuronal culture from mesencephalic embryonic @entity1 tissue in which 17-20 % of neurons were TH-positive when differentiated in vitro. NPD1 (100 nM) rescued cells from apoptosis induced by MPP+ and @entity7 , and the dendritic arbor of surviving neurons was examined using Sholl analysis. @entity7 , as well as MPP+ and its precursor @entity8 ( @entity8 ), severely promoted retraction of dendritic arbor distal segments, thus decreasing the maximum branch order reached. On average, NPD1 counteracted the effects of MPP+ on the dendritic arborization, but failed to do so in the @entity7 -treated neurons. However, @entity7 did decrease the Sholl intersection number from radii 25 to 125   m, and NPD1 did restore the pattern to control levels. Similarly, NPD1 partially reverted the dendrite retraction caused by MPP+ and @entity8 . These results suggest that the apoptosis occurring in mesencephalic TH-positive neurons is not a direct consequence of mitochondrial dysfunction alone and that NPD1 signaling may be counteracting this damage. These findings lay the groundwork for the use of the in vitro model developed for future studies and for the search of specific molecular events that NPD1 targets to prevent @entity3 in @entity4 .

title: The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of XXXX .

answer: @entity4


abstract: UNASSIGNED: The purpose of this study was to a) determine the heart rate variability (HRV) and saliva markers of immunity (salivary immunoglobulin A; sIgA) and stress ( @entity1 ; @entity0 ) responses to chronic training in elite swimmers with a disability; and b) identify the relationships between HRV, sIgA, @entity0 and training volume. Eight members of a high performance Paralympic swimming program were monitored for their weekly resting HRV, sIgA and @entity0 levels in the 14 weeks leading up to a major international competition. The 14 week training program included aerobic, anaerobic, power and speed, and taper training phases, while also incorporating two swimming step tests and two swimming competitions. Specific time (root mean square of the successive differences; RMSSD) and frequency (high frequency normalized units [HFnu]) domain measures, along with non-linear indices (standard deviation of instantaneous RR variability; @entity2 and short term fractal scaling exponent; a1) of HRV were used for all analyses with effects examined using magnitude-based inferences. Relationships between HRV and saliva markers were identified by Spearman rank rho (  ) correlation coefficients. Compared with week 1, @entity2 was very likely lower (96/4/0, ES = -2.21), while @entity0 was very likely elevated (100/0/0, ES = 2.32) at the beginning of week 7 for all athletes. The training program did not alter HRV or saliva whereas competition did. There were also no apparent differences observed for HRV, sIgA and @entity0 between each of the training phases during the 14 week swimming program. Correlations were observed between @entity0 and @entity2 (   = -0.212, p<0.05), along with @entity0 and mean HR (   = 0.309, p<0.05). These results show that high level national competition influences depresses HRV ( @entity2 ) and increases saliva biomarkers of stress ( @entity0 ). It appears that a well-managed and periodised swimming program can maintain these indices within normal baseline levels. The study also highlighted the parasympathetic nervous system influence on @entity0 .

title: Effect of Chronic Training on Heart Rate Variability, Salivary IgA and XXXX in Elite Swimmers with a Disability.

answer: @entity1


abstract: @entity0 telomerase RNA ( @entity8 ) expression in skin was examined by in situ hybridization analysis. All newborn foreskins examined (n = 5) expressed @entity8 in epidermal basal cells at moderate levels. Telomerase RNA was not detectable in most adult specimens from sun protected areas (six of seven), whereas all samples obtained from sun exposed areas (n = 8) showed moderate @entity8 signals in epidermal basal cells. Telomerase RNA was also detected at moderate to strong levels in basal cells of @entity6 , @entity7 , and the proliferative cells of the anagen hair bulb. @entity5 samples (14 of 15) had moderate to high @entity8 expression throughout the entire @entity1 , whereas @entity3 (seven of eight) showed variable intensities of @entity8 expression but only in the cells at the periphery of @entity1 nests. All @entity2 examined (n = 5) had moderate @entity8 expression in all @entity1 cells. The @entity8 signal intensities in @entity4 did not correlate with the age or sex of the donors, the clinical history of the lesions, or the histologic subtypes. To address whether @entity8 expression correlated with the proliferative state, sequential sections were stained with anti-Ki-67 antibody, a proliferation marker. In newborn foreskins, @entity3 , and @entity5 , the distributions of @entity8 and Ki-67 were similar but not always identical. Telomerase RNA was more abundant than Ki-67 in the basal and suprabasal layer of newborn foreskins, suggesting that @entity8 expression is present both in actively cycling and in resting cells.

title: In situ hybridization analysis of the expression of XXXX telomerase RNA in normal and pathologic conditions of the skin.

answer: @entity0


abstract: Ninety-three (93) cases of acute @entity2 were assessed using flow cytometry and cytochemistry and assigned to one of four categories: myeloid, lymphoid, biphenotypic, and non-diagnostic. In @entity2 designated as @entity1 or @entity4 by both methodologies, there was lineage agreement in all but 3 of 71 cases (95.8%). However, when nondiagnostic or biphenotypic diagnoses made by either methodology were included, complete agreement occurred in only 77.4% of cases. Of 37 cases designated myeloid origin by flow cytometry, 33 (89.2%) were read as myeloid by cytochemistry. The four discordant diagnosis were read as lymphoid (2) or as non-diagnostic (2). Eighty percent of @entity0 were diagnosed as such by both flow cytometry and cytochemistry; one early B cell @entity1 was diagnosed as myeloid and 8 as non-diagnostic. Fifty percent (50%) of flow cytometry defined T-cell @entity1 were considered non-diagnostic by cytochemistry as compared to 17% of the total @entity1 group. Of the remaining four designated non-T cell @entity1 by flow cytometry and non-diagnostic by cytochemistry, three were read by flow cytometry to be standard pre-B @entity1 and one an early B-cell @entity1 . Only 2/9 @entity2 considered biphenotypic by flow were identified as such by cytochemistry. Given (1) the potential importance of non-lineage expression in the prognosis of myeloid and @entity0 , (2) cytochemistry's impaired ability to diagnose biphenotypic, T-cell, and @entity3 , and (3) the increased costs incurred in diagnosis when both modalities are used, perhaps it is time to re-examine the utility of performing both flow cytometry and cytochemistry as initial testing for @entity2 categorization.

title: Flow cytometry with or without cytochemistry for the diagnosis of XXXX ?

answer: @entity4


abstract: Eleven pediatric @entity1 @entity0 were investigated for chromosomal @entity3 by interphase cytogenetics using chromosome specific (peri)centromeric probes for all the somatic and sex chromosomes. Results were compared with metaphase cytogenetic and flow cytometric derived DNA @entity3 data. Experiments performed on normal @entity0 cells using chromosome specific (peri)centromeric probes indicated that disomy could be recognized in a range of 89.1+/-2.7% (12.9)-96.8+/-0.2% (0.9) for the somatic chromosomes and in 98.1+/-0.4% (1.3) for the sex chromosomes. Using the cutoff level of the mean false monosomy and trisomy in the control cells +2 S.D., chromosome loss or gain for the somatic chromosomes could be revealed beyond a clonal ratio of 3.6-13.2% and 1.1-6.8%, respectively. The same value for the sex chromosomes was 3.5% and 0%, respectively. In 5 of 11 @entity0 the leukemic cells proved to be diploid with all three methods at both gross DNA and chromosome levels. Interphase cytogenetics revealed chromosome loss or gain in all of the remaining six @entity0 , however, the metaphase analysis indicated numerical aberration in only two @entity0 . In one of them only the increased chromosome number could have been detected without identifying the chromosomes involved and in the other one the two methods indicated trisomy for a different chromosome. Flow cytometric data showed @entity3 in three of the six @entity2 @entity0 . The results suggest that interphase cytogenetics might be more accurate compared with flow cytometry and metaphase analysis to reveal @entity3 .

title: Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric XXXX .

answer: @entity1


abstract: BACKGROUND: @entity2 following @entity1 are frequently subtle and are often overlooked. Even though these @entity2 may be less overt in nature, they are still debilitating to survivors. @entity2 have been shown to negatively impact cognition, mobility, and activities of daily living (ADL). There is little consistency across healthcare facilities regarding protocol for assessing vision following @entity1 . OBJECTIVE: This research was designed to describe a profile for @entity0 exhibiting @entity2 following @entity1 , examine the role of occupational therapists in vision assessment, and discuss a potential model to provide a protocol for collaboration with an eye care professional as part of the rehabilitation team. METHODS: The sample consisted of 131 @entity0 in an inpatient rehabilitation (IPR) unit who were identified as having potential @entity2 . Occupational therapists on an IPR unit administered initial vision screenings and these @entity0 were subsequently evaluated by the consulting optometrist. Frequencies were calculated for the appearance of functional symptoms, diagnoses, and recommendations. Correlations were also computed relating diagnoses and recommendations made. RESULTS: All @entity0 referred by the occupational therapist for optometrist evaluation had at least one visual diagnosis. The most frequent visual diagnoses included: saccades (77.7%), pursuits (61.8%), and convergence (63.4%). There was also a positive correlation between number of functional symptoms seen by occupational therapists and visual diagnoses made by the optometrist (r    =    0.209, P    =    0.016). CONCLUSION: Results of this study support the need for vision assessment following @entity1 in IPR, confirm the role of occupational therapists in vision assessment, and support the need for an optometrist as a member of the rehabilitation team.

title: Review of experience with a collaborative eye care clinic in inpatient XXXX rehabilitation.

answer: @entity1


abstract: The purpose of this study was to examine avidity of immunoglobulin G (IgG) antibody for surface antigens of @entity1 in sera from @entity0 with @entity2 . The antigens used were whole cell antigens, lipopolysaccharides (LPS), and fimbriae of non-invasive @entity4 and invasive 16-1. Serum IgG titers for the P. gingivalis antigens were measured by enzyme-linked immunosorbent assay (ELISA) before and after periodontal initial preparation. IgG avidity was measured by @entity3 dissociation ELISA. IgG titers for the whole cell antigens of 16-1, LPS, and the fimbria antigens from both @entity1 strains were significantly higher in the @entity0 group than those in the control group, whereas values for avidities were significantly lower in @entity0 sera. Although we found a statistically significant decrease in the IgG titers of @entity0 following initial preparation, avidities against the fimbria antigen of invasive 16-1 strain increased. The present study showed that IgG antibodies elicited in @entity0 were different in their ability to respond to invasive @entity1 16-1 and to non-invasive 33277. The @entity0 sera with high IgG titers demonstrated low values for avidity, suggesting that IgG responses in @entity0 play a limited role in colonization inhibition or elimination of @entity1 . The data indicate that periodontally healthy individuals may have highly functional antibodies which may protect against @entity1 colonization. Our findings suggest that the ability to produce functional antibodies in the @entity0 group is lower than that in the periodontally healthy group, but the functional antibodies can be induced by the initial preparation.

title: Dynamics of serum immunoglobulin G avidity for XXXX in @entity2 .

answer: @entity1


abstract: The purpose of this study was to examine avidity of immunoglobulin G (IgG) antibody for surface antigens of @entity1 in sera from @entity0 with @entity2 . The antigens used were whole cell antigens, lipopolysaccharides (LPS), and fimbriae of non-invasive @entity4 and invasive 16-1. Serum IgG titers for the P. gingivalis antigens were measured by enzyme-linked immunosorbent assay (ELISA) before and after periodontal initial preparation. IgG avidity was measured by @entity3 dissociation ELISA. IgG titers for the whole cell antigens of 16-1, LPS, and the fimbria antigens from both @entity1 strains were significantly higher in the @entity0 group than those in the control group, whereas values for avidities were significantly lower in @entity0 sera. Although we found a statistically significant decrease in the IgG titers of @entity0 following initial preparation, avidities against the fimbria antigen of invasive 16-1 strain increased. The present study showed that IgG antibodies elicited in @entity0 were different in their ability to respond to invasive @entity1 16-1 and to non-invasive 33277. The @entity0 sera with high IgG titers demonstrated low values for avidity, suggesting that IgG responses in @entity0 play a limited role in colonization inhibition or elimination of @entity1 . The data indicate that periodontally healthy individuals may have highly functional antibodies which may protect against @entity1 colonization. Our findings suggest that the ability to produce functional antibodies in the @entity0 group is lower than that in the periodontally healthy group, but the functional antibodies can be induced by the initial preparation.

title: Dynamics of serum immunoglobulin G avidity for @entity1 in XXXX .

answer: @entity2


abstract: To understand the influence of the ascending path linking area 17 to area 18 of visual cortices, experiments were carried out in which a small neuronal population of area 17 was inactivated with @entity2 , while unitary responses were recorded in area 18. In the latter, cells are identified as belonging to the simple or complex family according to their firing pattern evoked in response to sine-wave gratings scrolling through the receptive fields. Anesthetized @entity1 were prepared for single-cell recordings. In area 17, a @entity2 -containing pipette was placed in superficial layers in order to inactivate reversibly a small neuronal population. Prior to blockade, the orientation tuning curves were obtained in both areas and the difference in optimal orientation between areas 17 and 18 was recorded. In area 18, cells were classified as simple or complex. The strategy was to study the reaction of neurons in area 18 prior to, during and after area 17 @entity0 . In most simple cells, whenever the difference in orientation was in the iso-range, that is when the difference in optimal orientations of the injected site (in area 17) and of the neuron in area 18 was less than 30 degrees, the @entity2 application produced a decline of the evoked discharges, whereas @entity2 injection augmented the evoked firing rate when the difference was in the cross-range (>60 degrees). In contrast to simple cells, @entity2 @entity0 enhanced the responses in the majority of complex cells with like orientations in both areas. When the difference between recording sites was in the cross-range, then area 17 @entity0 produced @entity3 . A tangential penetration of the injecting pipette, allowing injection of different orientation sites while testing the same unit in area 18, revealed that the latter could react with an enhancement or a decline of the responses as the injecting pipette shifted from iso (or cross) to cross (or iso) disparity in optimal orientations between areas 17 and 18. These results suggest that the path connecting area 17 to area 18 may be functionally discriminated on the basis of the orientation domain and cell types. In addition, our data suggest that the ascending visual streams are required to generate orientation specificity in area 18.

title: Influences of area 17 on neuronal activity of simple and complex cells of area 18 in XXXX .

answer: @entity1


abstract: @entity13 ( @entity13 ) is a @entity9 with a frequency of 1/2,000-3,000 among female live births. Characteristic findings are short stature and @entity7 . Short and @entity4 , low posterior hairline, broad chest, widespread nipples, @entity16 , short 4th and 5th metacarpals, multiple @entity14 , primary @entity12 , lack of secondary sexual characteristics, cardiovascular and @entity3 are the most common presentations. Most of the cases are infertile. Spontaneous pregnancy is unusual and the risk for @entity5 , @entity10 , @entity11 and @entity8 is increased. Fifty percent of the @entity0 have classical @entity13 (45,X). However mosaicism of 45,X/47,XXX is rare and accounts for 1.7% of the @entity13 cases. Some cases may not reflect the characteristic phenotype. Some cases with normal height, normal menstrual cyclus and fertility have been defined before. The case we present herein is a 26 years old @entity0 who was admitted to our clinic due to recurrent @entity6 . In her medical history she had @entity2 and @entity1 , in her family history her mother had recurrent @entity6 . The @entity0 's first, third, fourth, fifth and sixth pregnancies had resulted in @entity10 in the first trimester. She had a healthy daughter with 46,XX karyotype from her second pregnancy. A 45,X[8]/47,XXX[12] karyotype was detected by conventional cytogenetic analysis of the @entity0 who did not have dysmorphic findings. The mosaicism was confirmed by FISH analysis with @entity15 probe. Of the 100 cells evaluated, 65 of them had 3 signals of X chromosome while 35 had 1 signal. We present the case because of its scarcity in the literature.

title: A fertile XXXX with 45X/47XXX mosaicism.

answer: @entity0


abstract: @entity6 ( @entity6 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity8 ( @entity5 / @entity7 ) and @entity4 , with a control arm of @entity4 only. @entity4 has been shown to potentiate in vivo anti- @entity1 activity of @entity5 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity0 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity0 were evaluable. The 128 @entity0 finally included had a histologically documented metastatic @entity6 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity0 . The @entity0 randomized to the control arm (n = 63) received only @entity4 40 mg p.o. daily for at least 1 year or until progression. The @entity0 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity5 , leucocyte @entity7 in a treatment cycle of 42 days, as well as @entity4 p.o. In the absence of undue @entity3 or disease progression, these @entity0 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity0 in the @entity4 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity0 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity0 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity2 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity0 that managed at least one treatment cycle (42 days) of @entity5 / @entity7 . The adverse effects were more pronounced in the @entity5 / @entity7 group. Although the number of @entity0 is limited, the results raise doubt concerning immunotherapy with @entity5 and @entity7 as a routine treatment in the management of advanced @entity6 . The difference in cost of drugs and health care (drug costs per @entity0 : @entity5 / @entity7  27000 vs @entity4  360) as well as adverse effects caused by @entity5 / @entity7 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: XXXX -a randomized evaluation of @entity4 vs @entity5 , alpha-interferon (leucocyte) and @entity4 .

answer: @entity6


abstract: @entity6 ( @entity6 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity8 ( @entity5 / @entity7 ) and @entity4 , with a control arm of @entity4 only. @entity4 has been shown to potentiate in vivo anti- @entity1 activity of @entity5 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity0 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity0 were evaluable. The 128 @entity0 finally included had a histologically documented metastatic @entity6 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity0 . The @entity0 randomized to the control arm (n = 63) received only @entity4 40 mg p.o. daily for at least 1 year or until progression. The @entity0 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity5 , leucocyte @entity7 in a treatment cycle of 42 days, as well as @entity4 p.o. In the absence of undue @entity3 or disease progression, these @entity0 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity0 in the @entity4 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity0 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity0 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity2 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity0 that managed at least one treatment cycle (42 days) of @entity5 / @entity7 . The adverse effects were more pronounced in the @entity5 / @entity7 group. Although the number of @entity0 is limited, the results raise doubt concerning immunotherapy with @entity5 and @entity7 as a routine treatment in the management of advanced @entity6 . The difference in cost of drugs and health care (drug costs per @entity0 : @entity5 / @entity7  27000 vs @entity4  360) as well as adverse effects caused by @entity5 / @entity7 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: @entity6 -a randomized evaluation of @entity4 vs XXXX , alpha-interferon (leucocyte) and @entity4 .

answer: @entity5


abstract: @entity6 ( @entity6 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity8 ( @entity5 / @entity7 ) and @entity4 , with a control arm of @entity4 only. @entity4 has been shown to potentiate in vivo anti- @entity1 activity of @entity5 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity0 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity0 were evaluable. The 128 @entity0 finally included had a histologically documented metastatic @entity6 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity0 . The @entity0 randomized to the control arm (n = 63) received only @entity4 40 mg p.o. daily for at least 1 year or until progression. The @entity0 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity5 , leucocyte @entity7 in a treatment cycle of 42 days, as well as @entity4 p.o. In the absence of undue @entity3 or disease progression, these @entity0 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity0 in the @entity4 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity0 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity0 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity2 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity0 that managed at least one treatment cycle (42 days) of @entity5 / @entity7 . The adverse effects were more pronounced in the @entity5 / @entity7 group. Although the number of @entity0 is limited, the results raise doubt concerning immunotherapy with @entity5 and @entity7 as a routine treatment in the management of advanced @entity6 . The difference in cost of drugs and health care (drug costs per @entity0 : @entity5 / @entity7  27000 vs @entity4  360) as well as adverse effects caused by @entity5 / @entity7 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: @entity6 -a randomized evaluation of XXXX vs @entity5 , alpha-interferon (leucocyte) and @entity4 .

answer: @entity4


abstract: @entity6 ( @entity6 ) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, @entity8 ( @entity5 / @entity7 ) and @entity4 , with a control arm of @entity4 only. @entity4 has been shown to potentiate in vivo anti- @entity1 activity of @entity5 , and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The @entity0 were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 @entity0 were evaluable. The 128 @entity0 finally included had a histologically documented metastatic @entity6 , with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each @entity0 . The @entity0 randomized to the control arm (n = 63) received only @entity4 40 mg p.o. daily for at least 1 year or until progression. The @entity0 (n = 65) randomized to biotherapy received subcutaneous recombinant @entity5 , leucocyte @entity7 in a treatment cycle of 42 days, as well as @entity4 p.o. In the absence of undue @entity3 or disease progression, these @entity0 received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two @entity0 in the @entity4 -only group received immunotherapy when the disease progressed, but without any beneficial effect. All @entity0 received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of @entity0 was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of @entity2 , from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to @entity0 that managed at least one treatment cycle (42 days) of @entity5 / @entity7 . The adverse effects were more pronounced in the @entity5 / @entity7 group. Although the number of @entity0 is limited, the results raise doubt concerning immunotherapy with @entity5 and @entity7 as a routine treatment in the management of advanced @entity6 . The difference in cost of drugs and health care (drug costs per @entity0 : @entity5 / @entity7  27000 vs @entity4  360) as well as adverse effects caused by @entity5 / @entity7 are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

title: @entity6 -a randomized evaluation of @entity4 vs @entity5 , alpha-interferon (leucocyte) and XXXX .

answer: @entity4


abstract: OBJECTIVE: To explore the intervention of @entity9 on signal transduction and activating transcription factor expression of @entity1 ( @entity1 ) @entity0 . METHODS: Recruited were @entity1 @entity0 at Outpatient Department of @entity12 , Inpatient Department of @entity12 , Center for Digestive Endoscopy of College City Branch, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Southern Hospital affiliated to Southern Medical University from June 2010 to January 2011. They were assigned to the @entity1 group (33 cases) and the @entity2 -predominant @entity6 ( @entity6 ) group (30 cases). Another 30 healthy subjects were recruited as a healthy control group. Peripheral blood mononuclear cells (PBMCs) in vitro intervened by different concentrations @entity9 were taken from @entity1 @entity0 . @entity11 gene expressions in vitro intervened by different concentrations @entity9 were detected using Q-PCR. Expressions of @entity8 ( @entity8 ) , @entity10 , phosphorylated- @entity8 (p- @entity8 ), and p- @entity10 were detected using Western blot. Serum levels of @entity3 , @entity7 , @entity4 , and @entity5 were measured by ELISA. Effects of different concentrations @entity9 on expressions of PBMCs, and levels of @entity3 , @entity7 , @entity5 of @entity1 @entity0 were also detected. RESULTS: Compared with the negative control group, 40   mol @entity9 obviously decreased @entity11 gene expression of @entity1 @entity0 (P <0. 01). Compared with the healthy control group and the @entity6 group, p- @entity8 / @entity8 ratios increased, p- @entity10 / @entity10 ratios decreased, levels of @entity3 , @entity7 , @entity5 all increased in the US group (all P <0. 05). Compared with the negative control, 5 and 10   mol @entity9 groups, 20 and 40 moL @entity9 obviously decreased p- @entity8 / @entity8 ratios (all P <0. 05); 20 and 40   moL @entity9 obviously increased p- @entity10 / @entity10 ratios (all P <0. 05); 20 and 40   moL @entity9 obviously lowered levels of @entity3 and @entity7 , and elevated @entity5 levels (all P <0. 05). CONCLUSION: 40   moL @entity9 could in vitro inhibit p- @entity8 / @entity8 ratios, adjust p- @entity10 / @entity10 ratios and related cytokines, thereby balancing the immunity and relieving inflammatory reactions of @entity1 .

title: [Effect of XXXX on signal transduction and activating transcription factor expression in @entity1 @entity0 ].

answer: @entity9


abstract: OBJECTIVE: To explore the intervention of @entity9 on signal transduction and activating transcription factor expression of @entity1 ( @entity1 ) @entity0 . METHODS: Recruited were @entity1 @entity0 at Outpatient Department of @entity12 , Inpatient Department of @entity12 , Center for Digestive Endoscopy of College City Branch, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Southern Hospital affiliated to Southern Medical University from June 2010 to January 2011. They were assigned to the @entity1 group (33 cases) and the @entity2 -predominant @entity6 ( @entity6 ) group (30 cases). Another 30 healthy subjects were recruited as a healthy control group. Peripheral blood mononuclear cells (PBMCs) in vitro intervened by different concentrations @entity9 were taken from @entity1 @entity0 . @entity11 gene expressions in vitro intervened by different concentrations @entity9 were detected using Q-PCR. Expressions of @entity8 ( @entity8 ) , @entity10 , phosphorylated- @entity8 (p- @entity8 ), and p- @entity10 were detected using Western blot. Serum levels of @entity3 , @entity7 , @entity4 , and @entity5 were measured by ELISA. Effects of different concentrations @entity9 on expressions of PBMCs, and levels of @entity3 , @entity7 , @entity5 of @entity1 @entity0 were also detected. RESULTS: Compared with the negative control group, 40   mol @entity9 obviously decreased @entity11 gene expression of @entity1 @entity0 (P <0. 01). Compared with the healthy control group and the @entity6 group, p- @entity8 / @entity8 ratios increased, p- @entity10 / @entity10 ratios decreased, levels of @entity3 , @entity7 , @entity5 all increased in the US group (all P <0. 05). Compared with the negative control, 5 and 10   mol @entity9 groups, 20 and 40 moL @entity9 obviously decreased p- @entity8 / @entity8 ratios (all P <0. 05); 20 and 40   moL @entity9 obviously increased p- @entity10 / @entity10 ratios (all P <0. 05); 20 and 40   moL @entity9 obviously lowered levels of @entity3 and @entity7 , and elevated @entity5 levels (all P <0. 05). CONCLUSION: 40   moL @entity9 could in vitro inhibit p- @entity8 / @entity8 ratios, adjust p- @entity10 / @entity10 ratios and related cytokines, thereby balancing the immunity and relieving inflammatory reactions of @entity1 .

title: [Effect of @entity9 on signal transduction and activating transcription factor expression in XXXX @entity0 ].

answer: @entity1


abstract: OBJECTIVE: To explore the intervention of @entity9 on signal transduction and activating transcription factor expression of @entity1 ( @entity1 ) @entity0 . METHODS: Recruited were @entity1 @entity0 at Outpatient Department of @entity12 , Inpatient Department of @entity12 , Center for Digestive Endoscopy of College City Branch, Guangdong Provincial Hospital of Traditional Chinese Medicine, and Southern Hospital affiliated to Southern Medical University from June 2010 to January 2011. They were assigned to the @entity1 group (33 cases) and the @entity2 -predominant @entity6 ( @entity6 ) group (30 cases). Another 30 healthy subjects were recruited as a healthy control group. Peripheral blood mononuclear cells (PBMCs) in vitro intervened by different concentrations @entity9 were taken from @entity1 @entity0 . @entity11 gene expressions in vitro intervened by different concentrations @entity9 were detected using Q-PCR. Expressions of @entity8 ( @entity8 ) , @entity10 , phosphorylated- @entity8 (p- @entity8 ), and p- @entity10 were detected using Western blot. Serum levels of @entity3 , @entity7 , @entity4 , and @entity5 were measured by ELISA. Effects of different concentrations @entity9 on expressions of PBMCs, and levels of @entity3 , @entity7 , @entity5 of @entity1 @entity0 were also detected. RESULTS: Compared with the negative control group, 40   mol @entity9 obviously decreased @entity11 gene expression of @entity1 @entity0 (P <0. 01). Compared with the healthy control group and the @entity6 group, p- @entity8 / @entity8 ratios increased, p- @entity10 / @entity10 ratios decreased, levels of @entity3 , @entity7 , @entity5 all increased in the US group (all P <0. 05). Compared with the negative control, 5 and 10   mol @entity9 groups, 20 and 40 moL @entity9 obviously decreased p- @entity8 / @entity8 ratios (all P <0. 05); 20 and 40   moL @entity9 obviously increased p- @entity10 / @entity10 ratios (all P <0. 05); 20 and 40   moL @entity9 obviously lowered levels of @entity3 and @entity7 , and elevated @entity5 levels (all P <0. 05). CONCLUSION: 40   moL @entity9 could in vitro inhibit p- @entity8 / @entity8 ratios, adjust p- @entity10 / @entity10 ratios and related cytokines, thereby balancing the immunity and relieving inflammatory reactions of @entity1 .

title: [Effect of @entity9 on signal transduction and activating transcription factor expression in @entity1 XXXX ].

answer: @entity0


abstract: We report two cases of @entity2 . Case 1: A 44-year-old @entity0 suffered from severe itching in the right external auditory meatus for a year, and had also had @entity3 unguium for several years. He visited our outpatient clinic because of scaly erythema which had developed on the auricle. Otoscopic examination revealed yellow-brown dry cerumen and redness from the cartilaginous to the bony portion of the external auditory meatus. Case 2: A 14-year-old @entity0 , the son of Case 1, suffered from severe itching in the left external auditory meatus. He scratched the auditory meatus with an earpick which his father had used. Otoscopic examination revealed a similar lesion as in the father's case, although he had no history of @entity3 elsewhere on his body, including the auricle. Direct examination using a KOH method of the cerumen from both cases demonstrated numerous fungal elements. Fungal culture identified @entity4 . Both cases were successfully treated with oral @entity1 . We suggest that infection from father to son was transferred by the earpick.

title: [Two cases of XXXX ].

answer: @entity2


abstract: UNASSIGNED: Toll  -like receptors have been utilized in cancer therapeutic strategies in recent years. To the best of our knowledge, the systemic use of the @entity4 ( @entity4 ) agonist has not been investigated in a @entity0 model. In the current study, @entity1 growth following drug therapy was examined. Immunofluorescence and TUNEL staining were performed in order to examine the @entity1 vasculature and apoptosis, respectively. In addition, immunohistochemistry was used to assess @entity2 in @entity1 tissues. Activated CD4+  T cells in the peripheral blood were examined by flow cytometry. In the present study, it was identified that the @entity4 agonist, R848, exhibited a robust antitumoral effect. R848 @entity1 and induced @entity1 cell apoptosis. In addition, R848 increased high mobility group box  1 expression in @entity1 tissues and activated CD4+ T cells in the peripheral blood. A synergistic antitumoral effect of R848 and the anti  -angiogenic agent, @entity3 , was observed. The present findings suggest that the @entity4 agonist may be a potential adjuvant to potentiate the effect of anti  -angiogenic therapy.

title: Toll  -like receptor  7/8 agonist, R848, exhibits antitumoral effects in a XXXX model.

answer: @entity0


abstract: BACKGROUND: @entity3 ( @entity3 ) are rare @entity1 of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of @entity0 treated for metastatic disease. METHODS: We performed a retrospective analysis of 119 @entity0 treated for metastatic @entity3 . Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. RESULTS: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) @entity0 received >= 2 and >= 3 lines of therapy, respectively. The most commonly used agents included @entity4 and @entity5 . Median overall survival was 12.1 months. Median times to @entity1 progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 @entity0 evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. @entity2 , liposomal @entity2 and @entity4 resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. CONCLUSION: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic @entity3 , and outcomes are poor. @entity2 , liposomal @entity2 and @entity4 are reasonable and appropriate choices for monotherapy.    2015 S. Karger AG, Basel.

title: Outcomes of Systemic Therapy for @entity0 with XXXX .

answer: @entity3


abstract: BACKGROUND: @entity3 ( @entity3 ) are rare @entity1 of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of @entity0 treated for metastatic disease. METHODS: We performed a retrospective analysis of 119 @entity0 treated for metastatic @entity3 . Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. RESULTS: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) @entity0 received >= 2 and >= 3 lines of therapy, respectively. The most commonly used agents included @entity4 and @entity5 . Median overall survival was 12.1 months. Median times to @entity1 progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 @entity0 evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. @entity2 , liposomal @entity2 and @entity4 resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. CONCLUSION: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic @entity3 , and outcomes are poor. @entity2 , liposomal @entity2 and @entity4 are reasonable and appropriate choices for monotherapy.    2015 S. Karger AG, Basel.

title: Outcomes of Systemic Therapy for XXXX with @entity3 .

answer: @entity0


abstract: An asymptomatic 26-year-old @entity0 with mild @entity10 (11.6 g Hb/dl) was studied. All biochemical parameters, bone marrow histology and cytogenetics were normal. The Ham's and sucrose tests were negative. A flow cytometric analysis revealed that @entity9 and @entity3 staining was absent in 20% and 21% of the granulocytes, but erythrocytes and @entity5 -positive bone marrow cells were @entity9 and @entity3 positive. Seven months after the initial study, the @entity0 suffered an episode of @entity8 , with mild @entity1 , moderate @entity2 and a weak positive sucrose lysis test. A new flow cytometric analysis disclosed an increased percentage of @entity9 and @entity3 negative granulocytes and a 25% of erythrocytes with an intermediate pattern of fluorescence after @entity3 labelling. At fourteen months, a population of @entity9 -deficient erythrocytes was detected and the Ham's test became positive. The present report is, to our knowledge, the first case of smoldering @entity7 in a @entity0 with no previous @entity4 , or evident @entity6 . The diagnosis was established by flow cytometry of peripheral blood granulocytes, with apparently phenotipically normal progenitor cells in an early stage of the disease. Flow cytometry appears to be a useful tool in our knowledge of @entity7 evolution.

title: De novo smoldering XXXX : a flow cytometric diagnosis.

answer: @entity7


abstract: INTRODUCTION AND OBJECTIVES: The natural history of @entity9 remains unclear, mainly due to concurrent @entity4 or @entity3 . Since the presence of confounding factors is less likely in youngsters, they constitute a suitable study model to analyze early stages of @entity9 . @entity0 AND METHODS: We screened 33 young normotensive asymptomatic @entity0 with @entity1 . Mean age was 28 +/- 8 y (range 18 to 46 y) and there were 14 @entity0 . RESULTS: 2-D Echo showed normal left ventricular size and wall motion in all @entity0 but one. Radionuclide basal ejection fraction was 56.5 +/- 6.6% and increased to 63 +/- 7.4% (p < 0.02) on exercise. According to Rozansky criteria, 16 @entity0 had an abnormal response. Abnormal stress sestamibi was detected in 18 @entity0 and only 3 had reversible defects. Coronary angiography was performed in 11 @entity0 with at least one abnormal non-invasive study response. Coronary angiography revealed normal vessels in all @entity0 and left anterior descending blood flow velocity (Doppler) increased 4 fold after @entity8 infusion. Left ventricular biopsies showed @entity7 (either nuclear or cellular) in 11, myocytolysis in 6, @entity2 in 9 and lipid deposits in 4. Morphometric analysis of cardiac samples comparing the @entity1 group and a control group showed that the volume fraction of @entity2 (0.19 +/- 0.06 vs 0.10 +/- 0.06; p < 0.01), fiber area -mu2- (1,062 +/- 547 vs 600 +/- 167; p < 0.02) and fiber diameter -mu- (24.2 +/- 3.3 vs 15.1 +/- 3.4; p < 0.001) were higher in the former; and volume fraction of the myocytes was higher in the latter (0.71 +/- 0.006 vs 0.89 +/- 0.07; p < 0.001). CONCLUSIONS: @entity6 , not related to @entity5 , is frequent in asymptomatic young @entity1 @entity0 . Abnormal pathologic findings are common in the type of cell @entity7 , @entity2 , myocytolysis and lipid deposits.

title: [Anatomopathological bases of latent ventricular dysfunction in insulin-dependent XXXX ].

answer: @entity1


abstract: OBJECTIVE: Increased peritoneal vasculature has been reported in long-term @entity3 ( @entity3 ), and vascular endothelial growth factors (VEGFs) have been found in dialysate. High concentrations of @entity4 or @entity5 , @entity4 degradation products (GDPs), and low pH of dialysis solutions are all possible factors in increased peritoneal @entity1 synthesis. In this study, we investigated the effects of high @entity4 dialysis solutions on @entity1 synthesis by peritoneal vascular endothelial cells (PVECs). METHODS: The PVECs were isolated from @entity2 omentum and were incubated for 4 hours in three different culture media [M199 media (control), conventional dialysis solutions containing 4.25% @entity4 diluted with an equal volume of M199 media (HGD), and M199 media containing 118 mmol/L @entity6 as an osmolar control ( @entity6 )]. Levels of @entity1 protein in the culture supernatant were measured by ELISA, and mRNA expression was determined by Northern blot analysis. Data are presented as percent of control. RESULTS: After incubation for 4 hours, the number of cells did not differ between the 3 groups. Levels of @entity1 in culture supernatant were significantly higher in the HGD group (124% +/- 19%, p = 0.006) as compared with the control and @entity6 (85% +/- 10%) groups. The mRNA expression of @entity1 appeared to be higher in the HGD group (128% +/- 49%) than in the control and @entity6 (94% +/- 18%) groups. CONCLUSION: High @entity4 dialysis solutions increased @entity1 synthesis by PVECs. The relationship between @entity1 synthesis by PVECs and neovascularization of the peritoneum observed in long-term @entity3 @entity0 has to be studied further.

title: High XXXX dialysis solutions increase synthesis of vascular endothelial growth factors by peritoneal vascular endothelial cells.

answer: @entity4


abstract: UNASSIGNED: @entity2 (AuNPs) of ~5nm core size and Zeta-potential of -35mV, having absorption maximum and plasmon resonance in the range of 510-570nm, were studied as a potential @entity3 -channel opener in vascular smooth muscle (SM) cells. Experimental design of the study comprised SM contractile recordings. When externally applied to the organ bath, AuNPs (10(-6)-3*10(-4)M) led to decrease in amplitude of @entity1 -induced contractions in a concentration-dependent and endothelium-independent manner in SM thoracic aorta, with mean value of pD2 (-log EC50) 4.2  0.03, Emax=55  4%. Being added to the bath solution in concentration of 10(-4)M, AuNPs significantly increased whole cell peak outward current at +70mV from 32  2pA/pF to 59  5pA/pF (n=14, P<0.05). External irradiation using a 5mW/532nm green laser, to facilitate plasmon resonance, led to an increment in the AuNPs-induced macroscopic outward @entity0 current (IK) from 59  5pA/pF to 74  1pA/pF (n=10, P<0.05). @entity5 (500nM), when added to the external bathing solution, significantly decreased AuNPs-induced increment of IK in SM cells. Single channel recordings provided a direct confirmation of @entity4 activation by AuNPs at the single-channel level. Application of AuNPs to the bath potentiated @entity4 activity with a delay of 1-2min, as was seen initially by more frequent channel openings followed by the progressive appearance of additional open levels corresponding to multiple openings of channels with identical single-channel amplitudes. Eventually, after 10-15min in the presence of AuNPs and especially when combined with the green laser illumination, there was a massive increase in channel activity with >10 channels evident. When irradiated by laser, AuNPs significantly increased the amplitude of maximal AuNPs-induced relaxation from 55  5% to 85  5% (n=10, P<0.05) while the sensitivity of SM to AuNPs was without changes. In summary, plasmonic AuNPs possess the ability to activate @entity4 channel opening in vascular SM. Laser irradiation facilitates this effect due to local plasmon resonance that, in turn, further increases @entity4 channel activity causing SM relaxation.

title: Plasmonic gold nanoparticles possess the ability to open XXXX channels in rat thoracic aorta smooth muscles in a remote control manner.

answer: @entity0


abstract: RATIONALE: It has been proposed that @entity2 ( @entity3 ) reflects free @entity1 -radical lipid peroxidation and can be useful as a biomarker to track this process. For the analysis of @entity3 molecules in humid air by selected ion flow tube mass spectrometry (SIFT- @entity0 ), the rate coefficients and the ion product distributions for the reactions of the SIFT- @entity0 reagent ions with volatile @entity3 in the presence of water vapour are required. METHODS: The SIFT technique has been used to determine the rate coefficients and ion product distributions for the reactions of @entity5 , NO(+) and @entity4 (+   ) with gas-phase @entity3 . In support of the SIFT- @entity0 analysis of @entity3 , solid-phase microextraction, SPME, coupled with gas chromatography/mass spectrometry, GC/ @entity0 , has been used to confirm the identification of @entity3 . RESULTS: The primary product ions have been identified for the reactions of @entity5 , NO(+) and @entity4 (+   ) with @entity3 and the formation of their hydrates formed in humid samples is described. The following combinations of reagent and the analyte ions (given as m/z values) have been adopted for SIFT- @entity0 analyses of @entity3 in the gas phase: @entity5 : 109; NO(+): 89, 102; @entity4 : 72, 90, 108, 126. The detection and quantification of @entity3 released by a cell culture by SIFT- @entity0 are demonstrated. CONCLUSIONS: This detailed study has provided the kinetics data required for the SIFT- @entity0 analysis of @entity3 in humid air, including exhaled breath and the headspace of liquid-phase biogenic media. The detection and quantification by SIFT- @entity0 of @entity3 released by a cell culture are demonstrated. Copyright    2015 John Wiley _ Sons, Ltd.

title: Direct detection and quantification of XXXX vapour in humid air using selected ion flow tube mass spectrometry supported by gas chromatography/mass spectrometry.

answer: @entity2


abstract: BACKGROUND: In 2006, Australia adopted a revised cervical cytology terminology system, known as the Australian Modified Bethesda System (AMBS). One substantial change in the AMBS was the introduction of the diagnostic category of @entity4 ( @entity4 ) of undetermined significance. AIM: The aim of this study was to investigate the incidence of histologically confirmed high-grade cervical @entity2 ( @entity1 ( @entity1 ) grades 2 and 3 and @entity7 (ACIS)), @entity6 and @entity3 in @entity0 presenting with @entity4 on cervical cytology. METHODS: A seven-year retrospective study examining clinical outcomes of @entity0 with @entity4 on a screening cervical smear. Cytology and histology results were extracted from the Western Australia Cervical Screening Registry, and time-to-event analysis was used to predict the odds of having or developing in  situ and invasive @entity1 . RESULTS: @entity4 was reported in index smears from 0.093% (584/622754) @entity0 during the study period. No follow-up was available in 35 @entity4 cases. Sixty-five of the remaining 549 @entity0 (11.8%) had, or developed, high-grade cervical @entity2 within five years of their index @entity4 diagnosis. @entity3 was diagnosed in 21 @entity0 and @entity1 in four @entity0 during the follow-up period. CONCLUSION: Cytologic demonstration of @entity4 requires careful gynaecologic evaluation, particularly in younger @entity0 who may be found to have either high-grade squamous ( @entity1 ) or glandular (ACIS) lesions, while in older @entity0 , the possibility of @entity5 needs to be considered.

title: Risk of high-grade cervical @entity2 and gynaecological @entity1 following the cytologic diagnosis of XXXX of undetermined significance: A retrospective study of a state-wide screening population in Western Australia.

answer: @entity4


abstract: BACKGROUND: In 2006, Australia adopted a revised cervical cytology terminology system, known as the Australian Modified Bethesda System (AMBS). One substantial change in the AMBS was the introduction of the diagnostic category of @entity4 ( @entity4 ) of undetermined significance. AIM: The aim of this study was to investigate the incidence of histologically confirmed high-grade cervical @entity2 ( @entity1 ( @entity1 ) grades 2 and 3 and @entity7 (ACIS)), @entity6 and @entity3 in @entity0 presenting with @entity4 on cervical cytology. METHODS: A seven-year retrospective study examining clinical outcomes of @entity0 with @entity4 on a screening cervical smear. Cytology and histology results were extracted from the Western Australia Cervical Screening Registry, and time-to-event analysis was used to predict the odds of having or developing in  situ and invasive @entity1 . RESULTS: @entity4 was reported in index smears from 0.093% (584/622754) @entity0 during the study period. No follow-up was available in 35 @entity4 cases. Sixty-five of the remaining 549 @entity0 (11.8%) had, or developed, high-grade cervical @entity2 within five years of their index @entity4 diagnosis. @entity3 was diagnosed in 21 @entity0 and @entity1 in four @entity0 during the follow-up period. CONCLUSION: Cytologic demonstration of @entity4 requires careful gynaecologic evaluation, particularly in younger @entity0 who may be found to have either high-grade squamous ( @entity1 ) or glandular (ACIS) lesions, while in older @entity0 , the possibility of @entity5 needs to be considered.

title: Risk of high-grade cervical XXXX and gynaecological @entity1 following the cytologic diagnosis of @entity4 of undetermined significance: A retrospective study of a state-wide screening population in Western Australia.

answer: @entity2


abstract: BACKGROUND: In 2006, Australia adopted a revised cervical cytology terminology system, known as the Australian Modified Bethesda System (AMBS). One substantial change in the AMBS was the introduction of the diagnostic category of @entity4 ( @entity4 ) of undetermined significance. AIM: The aim of this study was to investigate the incidence of histologically confirmed high-grade cervical @entity2 ( @entity1 ( @entity1 ) grades 2 and 3 and @entity7 (ACIS)), @entity6 and @entity3 in @entity0 presenting with @entity4 on cervical cytology. METHODS: A seven-year retrospective study examining clinical outcomes of @entity0 with @entity4 on a screening cervical smear. Cytology and histology results were extracted from the Western Australia Cervical Screening Registry, and time-to-event analysis was used to predict the odds of having or developing in  situ and invasive @entity1 . RESULTS: @entity4 was reported in index smears from 0.093% (584/622754) @entity0 during the study period. No follow-up was available in 35 @entity4 cases. Sixty-five of the remaining 549 @entity0 (11.8%) had, or developed, high-grade cervical @entity2 within five years of their index @entity4 diagnosis. @entity3 was diagnosed in 21 @entity0 and @entity1 in four @entity0 during the follow-up period. CONCLUSION: Cytologic demonstration of @entity4 requires careful gynaecologic evaluation, particularly in younger @entity0 who may be found to have either high-grade squamous ( @entity1 ) or glandular (ACIS) lesions, while in older @entity0 , the possibility of @entity5 needs to be considered.

title: Risk of high-grade cervical @entity2 and gynaecological XXXX following the cytologic diagnosis of @entity4 of undetermined significance: A retrospective study of a state-wide screening population in Western Australia.

answer: @entity1


abstract: BACKGROUND/AIMS: Rituximab and glucocorticoids are a non-inferior alternative to @entity3 and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated @entity4 (AAV) @entity0 with moderate @entity1 . The efficacy and safety of this approach in @entity0 with severe @entity1 are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in @entity0 with AAV and ANCA-negative @entity4 presenting with severe @entity1 . METHODS: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. @entity0 with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of  <=20 ml/min/1.73 m(2) treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen @entity0 met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The secondary outcomes were eGFR at 6 months, @entity2 ( @entity2 ), survival rates and adverse events. RESULTS: All @entity0 were Caucasian, and 57% were male. The mean eGFR was 12 ml/min/1.73 m(2) at diagnosis. All @entity0 achieved remission with a median time to remission of 55 days. Seven @entity0 required dialysis at presentation of which 5 @entity0 recovered renal function and discontinued dialysis by 6-month follow-up. The mean eGFR for the 11 @entity0 without @entity2 who completed 6-month follow-up was 33 ml/min/1.73 m(2). Four @entity0 ultimately developed @entity2 , and one died during the follow-up period. CONCLUSION: @entity0 with AAV and severe @entity1 achieve high rates of remission and dialysis independence when treated with rituximab and glucocorticoids without @entity3 .    2015 S. Karger AG, Basel.

title: Treatment of Severe XXXX in ANCA Positive and Negative Small @entity4 with Rituximab.

answer: @entity1


abstract: BACKGROUND/AIMS: Rituximab and glucocorticoids are a non-inferior alternative to @entity3 and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated @entity4 (AAV) @entity0 with moderate @entity1 . The efficacy and safety of this approach in @entity0 with severe @entity1 are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in @entity0 with AAV and ANCA-negative @entity4 presenting with severe @entity1 . METHODS: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. @entity0 with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of  <=20 ml/min/1.73 m(2) treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen @entity0 met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The secondary outcomes were eGFR at 6 months, @entity2 ( @entity2 ), survival rates and adverse events. RESULTS: All @entity0 were Caucasian, and 57% were male. The mean eGFR was 12 ml/min/1.73 m(2) at diagnosis. All @entity0 achieved remission with a median time to remission of 55 days. Seven @entity0 required dialysis at presentation of which 5 @entity0 recovered renal function and discontinued dialysis by 6-month follow-up. The mean eGFR for the 11 @entity0 without @entity2 who completed 6-month follow-up was 33 ml/min/1.73 m(2). Four @entity0 ultimately developed @entity2 , and one died during the follow-up period. CONCLUSION: @entity0 with AAV and severe @entity1 achieve high rates of remission and dialysis independence when treated with rituximab and glucocorticoids without @entity3 .    2015 S. Karger AG, Basel.

title: Treatment of Severe @entity1 in ANCA Positive and Negative Small XXXX with Rituximab.

answer: @entity4